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• Ehlers-Danlos Syndrome (EDS) is a rare heterogeneous group of inherited collagen disorders.
• A cohort of EDS patients was investigated for bleeding tendency and hemostatic abnormalities.
• EDS is associated with an increased risk of bleeding.
• EDS patients have platelet function abnormalities, whose severity correlates with bleeding risk.
Summary. Background: Ehlers-Danlos syndrome (EDS)
includes a heterogeneous group of connective tissue disorders affecting skin, bones, vessels, and other organs. Patients with EDS have an increased risk of bleeding, but a comprehensive study of hemostasis in EDS patients is lacking. Objective: To investigate the bleeding tendency of a cohort of patients with EDS by using the Bleeding Assessment Tool of the ISTH, the bleeding severity score (BSS). Methods: The BSS was defined as abnormal when it was ≥ 4 in men and ≥ 6 in women. Patients with a bleeding tendency were compared with those without in terms of type and number of hemostatic abnormalities. Results: Fifty-nine of 141 patients with EDS (41.7%) had an abnormal BSS. Prothrombin time and activated partial thromboplastin time were slightly prolonged in 10 patients (7.1%) because of mild coagulation factor deficiencies, which were not responsible for the bleeding diathesis. von Willebrand factor antigen, ristocetin cofactor, endogenous thrombin potential and platelet count were normal in all patients. At least one platelet function abnormality was found in 53 patients (90%) with an abnormal BSS and in 64 (78%) with a normal BSS (adjusted odds ratio [OR] 2.55, 95% confidence interval [CI] 0.87-7.48). The risk of bleeding progressively increased with the number of platelet function abnormalities, reaching an OR of 5.19 (95% CI 1.32-20.45) when more than three abnormalities were detected. Conclusions: Our results show that nearly half of patients with EDS have an abnormal BSS, which, in 90% of cases, appear, at least in part, to be attributable to platelet function abnormalities. Abnormalities of primary hemostasis may contribute to the risk of bleeding in patients with EDS.
Introduction
Ehlers-Danlos syndrome (EDS) comprises a heterogeneous group of heritable collagen disorders characterized by fragility of soft connective tissue, joint hypermobility, skin hyperextensibility, and easy bruising and bleeding [1] . According to clinical, pathological and genetic features, the 2017 International Classification for EDS recognizes 13 different subtypes of EDS [2] . Among them, the classic EDS (cEDS) and hypermobile EDS (hEDS) subtypes are the most common, with the prevalence in the general population varying between 1 : 2500 and 1 : 5000 [3] . Vascular EDS (vEDS) represents only 5-10% of EDS cases, giving a prevalence of 1 : 10 000-1 : 25 000 [4] , is characterized by a severe phenotype, and has the worst prognosis. Other subtypes of EDS, such as the kyphoscoliotic, arthrochalasic and dermatosparaxis subtypes, are very rare. The bleeding phenotype of patients with EDS varies from mild bruising in those with cEDS and hEDS to severe and sometimes fatal bleeding in those with vEDS. The most common bleeding symptoms are bruising, hematoma, and menorrhagia, the latter reported in up to 76% of women in a recent large cohort study [5] . Severe vascular complications such as arterial aneurysms, arterial dissections and intracranial hemorrhages can also occur in patients with non-vascular subtypes [6] . It is well recognized that a strong contributory factor for bleeding is the fragility of subcutaneous and perivascular tissues that is typical of collagenopathies, but hemostasis abnormalities can increase the risk of bleeding. In the past decade, several case reports and small case series described bleeding manifestations in patients with EDS. Deficiencies in factor XI and von Willebrand factor (VWF) were recognized [7, 8] , as well as platelet aggregation abnormalities [9] [10] [11] [12] . However, because of the rarity of the disease and the highly specialized laboratory tests, a well-conducted study of primary and secondary hemostasis in patients with EDS is lacking.
The aims of this study were to assess the bleeding tendency of adult patients with EDS by using a standardized international score, and to evaluate whether the presence of primary or secondary hemostasis abnormalities is associated with the risk of bleeding.
Patients and methods

Design and study population
This cohort study was carried out at the A. Bianchi Bonomi Hemophilia and Thrombosis Center and Unit of Occupational Medicine of the Fondazione IRCCS Ca' Granda -Ospedale Maggiore Policlinico of Milan, Italy. The latter unit is a regional referral center for patients with EDS who are followed at least on a yearly basis. All patients aged > 18 years seen between September 2014 and September 2016 for a follow-up visit or for the first evaluation were included in the study. The diagnosis of EDS was made according to Villefranche revised nosology, in the presence of at least two major criteria for the disease [3] . The classification was then updated according to the one proposed by the International EDS Consortium [2] . Patients who reported the intake of drugs interfering with platelet function or blood coagulation (i.e. non-steroidal anti-inflammatory or anticoagulant drugs) within the previous 10 days were asked to come back for blood sampling after at least 7 days of discontinuation. Clinical features, a family history of EDS (the presence of at least one first-degree relative meeting the clinical criteria), subtype and date of EDS diagnosis, minor and major bleeding events (defined according to published criteria) [13] , medical history and comorbidities were retrieved from medical records. Weight and height were measured, and the body mass index (BMI) was calculated as kg m
À2
. Information on previous exposures to conditions involving a risk of bleeding, such as surgery or tooth extractions, and on the presence of vascular aneurism or ectasia were collected. Surgery was considered to be minor or major according to established criteria [14] . A validated questionnaire, i.e. the Bleeding Assessment Tool of the ISTH (BAT-ISTH) (including questions on epistaxis, tooth extractions, cutaneous, oral cavity, gastrointestinal or cerebral nervous system bleeding, bleeding from minor wounds, surgery, menorrhagia, postpartum hemorrhage, muscle hematoma, and hemarthrosis during the patient's lifetime), was administered by a trained physician, and the bleeding tendency was expressed in terms of the bleeding severity score (BSS) [15] . The BSS was considered to be abnormal and related to a bleeding tendency when it was ≥ 4 in men and ≥ 6 in women, as recently suggested [16] .
The study was approved by the Ethics Committee of our Hospital (Milano Area B, approval number 931/ 2014), and patients gave their written informed consent to participate in the study.
Laboratory tests
Coagulation tests were performed in tubes containing 0.109 M sodium citrate as anticoagulant, and blood was taken from an antecubital vein. Citrated blood was centrifuged at 3800 9 g for 15 min in order to obtain platelet-free plasma for determination of prothrombin time (PT) ratio and activated partial thromboplastin time (APTT) ratio (Instrument Laboratory, Milan, Italy). If the PT or APTT were prolonged increased (i.e. higher than the 97.5th percentile of the normal laboratory reference range), FVII or FVIII, FIX, FXI and FXII plasma levels were measured. If both PT and APTT were prolonged, FX, FV and fibrinogen were also measured. Normal coagulation factor activity level is set by our laboratory at ≥ 70%, with the exception of FVIII, for which the normal level is > 50%. VWF antigen (VWF: Ag) and VWF ristocetin cofactor activity (VWF:RCo) were measured with standard methods. Endogenous thrombin potential (ETP) was tested in platelet-poor plasma as previously reported (Synapse b.v., Maastricht, the Netherlands) [17] . Lag time, peak height and time to peak were measured with or without thrombomodulin. The area under the thrombin generation curve represents the total amount of thrombin formed over time; the results were expressed as ETP. Normal ranges were considered to be between the 2.5th and 97.5th percentile of ETP values among a population of healthy individuals. For platelet function tests, citrated blood was centrifuged for 15 min at 190 9 g to obtain platelet-rich plasma (PRP). The remaining blood was further centrifuged at 1100 9 g to obtain platelet-poor plasma. Platelet aggregation studies were performed within 3 h from sample collection, on a Chrono-Log lumiaggregometer (Mascia Brunelli, Milan, Italy). Four hundred and fifty microliters of PRP were mixed with 50 lL of luciferin-luciferase, and gently stirred at 1000 r.p.m. at 37°C. After 30 s, an agonist (ADP at a final concentration of 4 lmol L À1 , collagen 2 lg mL À1 , U46619, a thromboxane A 2 analog, at a final concentration of 0.5 lmol L
À1
, or thrombin receptor-activating peptide at 10 lmol L À1 ) was added, and the aggregation/release reaction was followed for an additional 3 min. A standard curve obtained with a fixed dose of ATP, added to platelet-poor plasma, was used to quantify ATP secretion (expressed in nmol per 10 8 platelets). Abnormal platelet aggregation or secretion was defined when the results were below the 5th percentile of the aggregation or secretion values among 80 healthy individuals tested in the same study period. Severity of platelet dysfunction was defined according to the number of platelet abnormalities.
Hemoglobin and creatinine clearance (Cockroft-Gault formula) were also measured, because anemia and impaired renal function are associated with an increased risk of bleeding [18, 19] .
Statistical analysis
Mean and standard deviation were used to describe continuous variables that were normally distributed; otherwise, median and interquartile range were calculated. Categorical variables were presented as count and percentage. Linear regression was used to correlate VWF:Ag, VWF:RCo and age at enrollment with BSS, and b estimates with 95% confidence intervals (CIs) were calculated. The Mann-Whitney U-test was used to compare median ETP values between groups. The Spearman correlation coefficient (r s ) was used to evaluate the relationship between BSS and age at blood sampling. Logistic regression models were used for the main analysis on the association between risk of bleeding, expressed as an abnormal BSS, and platelet function abnormalities. Odds ratios (ORs) with 95% CIs were calculated as measures of relative risk. Multivariable logistic models were used to take into account possible confounders, i.e. age at blood sampling, sex, BMI, hemoglobin, and renal function. Statistical analyses were performed with IBM SPSS STATISTICS for Windows, Version 23.0 (IBM, Armonk, NY, USA).
Results
Patient characteristics
One hundred and fifty-three patients with EDS were screened for inclusion in the study. Nine of them were excluded because of refusal to temporarily interrupt the intake of non-steroidal anti-inflammatory drugs (n = 4) or inability to complete the BAT-ISTH questionnaire (n = 5). Three patients did not meet the EDS diagnostic criteria. No patient was receiving anticoagulant treatment. Hence, 141 patients formed the study cohort. The BSS, ranging from 0 to 16, was normal in 82 (58%) patients and abnormal in 59 (42%) patients. Table 1 shows the baseline characteristics of patients, which were similar in those with a normal BSS and an abnormal BSS. The most common subtypes of EDS were cEDS and hEDS. Only seven patients had the vEDS subtype, and five of them had an abnormal BSS. All vascular patients were positive for defined mutations in COL3A1 [20] . Fortyseven patients with cEDS underwent genetic testing, which gave positive results in 49% of them. For 20 cEDS patients, genetic testing is still ongoing. Detailed clinical characteristics of cEDS patients are shown in Table S1 . In the remaining patients, genetic testing for confirmation of EDS was not systematically performed, and the diagnosis of the disease was mainly clinical. There was no correlation between age at blood sampling and BSS (r s = 0.145, P = 0.05); the linear regression coefficient (b) was 0.04 (95% CI 0.004-0.09). No patient had a previous diagnosis of hemostasis abnormalities. Platelet counts and fibrinogen levels were normal in all patients. Conditions associated with an increased risk of bleeding are shown in Table 2 , and were similar in patients with a normal and an abnormal BSS. In particular, 72% of patients experienced at least one major surgery, tooth extractions were more prevalent in the group with an abnormal BSS (70% versus 16%), and the chronic use of non-steroidal antiinflammatory drugs was similar in the two groups. Major bleeding occurred in six (9%) patients with cEDS, in 11 (17%) patients with hEDS, and in four (57%) patients with vEDS. Overall, there were 26 bleeding episodes: seven spontaneous (two in patients with vEDS, three in patients with cEDS, and two in patients with hEDS) and 19 provoked (three in patients with vEDS, five in patients with cEDS, and 11 in patients with hEDS). Provoked bleeds occurred during or soon after surgery (n = 4; two in patients with vEDS, and two in patients with hEDS), trauma (n = 5; one in patients with cEDS, and four in patients with hEDS), or delivery (n = 9; one in patients with vEDS, four in patients with cEDS, and four in patients with hEDS). The remaining major bleed was a hemoperitoneum caused by breaking of the corpus luteum in a patient with hEDS.
Hemostasis tests
As shown in Table 3 , 10 patients of 141 had a slight prolongations of PT or APTT resulting from mild coagulation factor deficiencies not associated with abnormal BSSs. VWF:Ag levels (mean of 116.2% AE 34.4%) and VWF:RCo (mean of 94.7% AE 26.5%) were normal in all patients, as was ETP in all determinations. There was no correlation between levels of VWF:Ag or VWF:RCo and BSS as a continuous variable (respectively: b = À 0.01, 95% CI À 0.05 to 0.03; and b = 0.02, 95% CI À 0.03-0.07). Platelet function was normal in 24 patients, and in 117 (83%) patients at least one abnormality was found. Table 4 shows that 80 patients (56.7%) had a platelet aggregation abnormality in response to at least one of the four stimulating agents tested. Platelet secretion was abnormal in response to at least one stimulating agent in 111 patients (78.7%), and 60 (42.6%) had a combined aggregation and secretion abnormality. Platelet function was impaired mainly in response to ADP as the stimulating agent.
Impaired platelet function was associated with an abnormal BSS (Table 5 ). Having at least one platelet function abnormality doubled the risk of bleeding (adjusted OR 2.55, 95% CI 0.87-7.48). A dose-response effect between the severity of platelet dysfunction and the risk of bleeding was observed, and having more than three platelet function abnormalities increased the risk of bleeding five-fold (adjusted OR 5.19, 95% CI 1.32-20.45). The risk of bleeding associated with platelet function abnormalities and the separate effect of each confounder are shown in Table S2 . Combined platelet aggregation and secretion abnormalities were more common in patients with vEDS (71.4%), but at least one platelet function abnormality was detected in % 80% of patients, regardless of the subtype of EDS (Table 6) , and was present in 90% of patients with a BSS of > 5.
Discussion
This study shows an objective and quantifiable bleeding diathesis of a large cohort of patients with EDS, regardless of the subtype of the disorder. To assess the bleeding tendency of patients, we used the BSS obtained from the BAT-ISTH, which has been demonstrated to be a valid tool for identifying patients with abnormal hemostasis. Patients with EDS had no coagulation abnormalities nor reduced thrombin generation that may justify a bleeding tendency, but 80% of them showed an impairment of platelet function. The severity of platelet dysfunction was associated with a progressively increased risk of bleeding, although the majority of patients had a platelet dysfunction mainly in the ADP pathway. Ninety per cent of patients with a BSS of > 5 had a platelet function abnormality.
To date, several case reports or small case series have described hemostasis abnormalities in patients with EDS, but no correlation between their presence and the bleeding tendency assessed with a validated method has been performed. In the early 1990s, platelet aggregation abnormalities in response to ADP were found in 13 of 51 patients with EDS [7] . More recently, a study of 25 pediatric patients with hEDS showed that 56% of them had an abnormal bleeding score obtained with the Pediatric Bleeding Questionnaire (based on the BAT-ISTH), but coagulation and platelet function were not investigated [21] . Another study of 22 patients with vEDS [22] showed platelet aggregation abnormalities in 50% of them, but the laboratory methods used by the authors (rotational thromboelastrometry or Platelet Function Analyser-100) are less accurate than the light transmission aggregometry used by us, which is the gold standard method for investigating platelet aggregation [23] . Three other studies applied the BAT-ISTH score to predict platelet dysfunction in patients with bleeding diathesis and suspected inherited platelet function abnormalities. Although the first study failed to find an association in 76 patients [24] , the other two support the BAT-ISTH score as a useful tool for predicting platelet dysfunction in 161 and 91 patients [25, 26] . A BSS threshold of 5 appeared to be a reliable cut-off for identifying patients with bleeding tendency who require further laboratory investigation to detect platelet function abnormalities (almost 90%). To our knowledge, this is the largest cohort study of patients with EDS in whom bleeding diathesis has been objectively assessed and a comprehensive laboratory investigation has been performed. Some limitations need to be addressed. First, we investigated a cohort of adult patients followed by a single center, and our findings might not be generalizable to all patients with EDS. Because our hospital is a regional referral center for the disease, the possibility of having included the most severe patients cannot be ruled out. However, as no patient of our cohort was referred because of a bleeding tendency, this selection bias should have been minimized. On the other hand, the exclusion of patients who were chronically using non-steroidal anti-inflammatory drugs may have led to a selection of patients with bleeding diathesis. Second, only seven patients had vEDS, and no conclusions on hemostasis abnormalities in patients with this severe subtype of disease can be drawn. Third, the classification of EDS subtypes was mainly clinical, because the common hEDS does not have a corresponding genetic marker, and because, for several patients, genetic testing was ongoing or had not yet been performed. Fourth, although we observed a clear association between the number of platelet function abnormalities and the risk of bleeding, statistical significance of the point estimates was reached only for patients with more than three abnormalities. Finally, our study did not investigate the mechanistic relationship between EDS and impaired platelet function. Abnormal collagen biosynthesis is probably responsible for the bleeding tendency in patients with EDS, and, from our results, we can speculate that the altered structure of vessels may activate and exhaust platelets, which become less reactive to various stimulating agents. Almost half of the platelet dysfunctions were observed after stimulation with ADP, which was the most sensitive agent for detecting functional abnormalities.
In conclusion, nearly half of our patients with EDS had a bleeding diathesis as underlined by an abnormal BSS, regardless of the EDS subtype. Other than the contribution of impaired vascular integrity, which is expected in patients with a connective tissue disorder such as EDS, we found that the majority of patients with an abnormal BSS had platelet function abnormalities. As two-thirds of our patients with EDS have been exposed to major surgeries, our results can be applied to patients at high risk of bleeding. Patients with EDS, especially before surgery or invasive procedures, should be carefully evaluated to assess their bleeding tendency, and, in those with a strong bleeding history, platelet function tests should be performed in order to establish the most appropriate treatment.
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